Positive Antibody Persistence Data Reported for Valneva’s Chikungunya Vaccine

Saint-Herblain (France), December 3, 2024

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated. The three-year persistence data are also in line with positive twelve-month and two-year persistence data the Company reported in December 20221 and 20232, respectively.

Upon hearing the news that Valneva’s chikungunya vaccine, IXCHIQ®, has shown positive antibody persistence data three years after vaccination, it is clear that the company has made significant strides in the field of vaccine development. This is especially important given the prevalence of chikungunya virus in certain regions of the world.

With the long-lasting antibody persistence observed across all age groups investigated, it is evident that Valneva’s vaccine is effective in providing lasting immunity against chikungunya. This is great news for individuals who may be at risk of contracting the virus, as they can now rely on this vaccine for protection.

Furthermore, the consistent positive results reported by Valneva over the past few years demonstrate the reliability and efficacy of their vaccine. This is a testament to the hard work and dedication of the team behind the development of IXCHIQ®.

How This News Will Affect Me

As an individual who may be at risk of chikungunya virus exposure, the positive antibody persistence data reported by Valneva is reassuring. Knowing that there is a vaccine available that can provide long-lasting immunity gives me peace of mind and confidence in my own health and safety.

How This News Will Affect the World

The positive antibody persistence data reported by Valneva for their chikungunya vaccine has the potential to have a significant impact on global health. With a strong and long-lasting immunity demonstrated across all age groups, this vaccine has the potential to help prevent the spread of chikungunya virus in regions where it is endemic.

Conclusion

In conclusion, Valneva’s positive antibody persistence data for their chikungunya vaccine IXCHIQ® marks a significant step forward in the fight against this infectious disease. The promising results reported by the company are a testament to their dedication to improving global health and safety through innovative vaccine development.